EP Solutions SA (“EP Solutions”) has developed a highly innovative system for non-invasive epicardial and endocardial electrophysiology mapping (ECGi).
EP Solutions has its headquarters and operations in Yverdon-les-Bains, Switzerland, from where its worldwide R&D, Supply Chain and all commercial operations are managed.
The history of EP Solutions dates back to 2009 when it was founded under the name of Amycard LLC in Moscow, Russia.
In 2014 EP Solutions SA was incorporated in Switzerland after the acquisition and transfer of assets of Amycard LLC.
Since its foundation the company primarily focused on the development of innovative methods for non-invasive diagnostics and for interventional treatment of cardiac arrhythmias.
The EP Solutions system is a novel technology in ECGi class, allowing for simultaneous electrophysiology mapping on both epicardial and endocardial surfaces of the heart .
The company’s unique real-time cardiac mapping technology is based on over seven years of clinical research with more than 750 patients.
The company’s technology is protected through a highly competitive portfolio of intellectual property rights in terms of patents and trade secrets in key markets.
EP Solutions holds a CE-Mark from BSI for its products and has launched its commercial roll-out in Europe.
EP Solutions is in the process of obtaining FDA approval in the USA.
The company’s management team has longtime experience and unique know-how in the field of electrophysiology and cardiology.
Highly distinguished clinical investigators and advisors are actively supporting product development.